Hint mode is switched on Switch off

Novo Nordisk, American depositary receipt (ADR)
NVO, US6701002056

Add a stock to WL
Choose all Reset all
Novo Nordisk, сountry — Denmark
No trading data
Data display in a chart | table
Source of information - PJSC "MOEX". Further disctribution of MOEX information is prohibited without prior consent with PJSC "MOEX".
Source of information - PJSC "MOEX". Further disctribution of MOEX information is prohibited without prior consent with PJSC "MOEX".
No data
from
to
ADD-IN
Cbonds add-in API
bond data api
Authorization required
You need to request access
More than 2,500 records have been found, please specify your request
No data for the selected period

Upgrade to Premium features

Cbonds consolidates global bond, stock, ETF and indices data into a single platform — so you can analyze faster, make informed investment decisions and outperform the market

Get access
Welcome to Cbonds

  • Full access to the largest bond database

    Bond parameters,
    prospectuses

  • Seamless
    Data export

    Analyze the data in the most efficient way

  • Bond pricing

    Current & historical quotes from 400+ stock exchanges & OTC market

  • Smart risk assessment

    Credit ratings, financial reports

Get access

Latest quotes

Get access to the largest financial database

Try in 7-days Demo access

Free for company representative

  • Evaluate advanced analytical tools
  • Get full online access to the database
  • Try our powerful bond screener
  • Track bond prices from 400+ sources

Get access to the largest financial database

Representative of the company 7 days FREE trial

Professional access to the data

Private investor

Individual access

Dividends

Analysts forecasts

  • median ***
  • average ***
  • min ***
  • max ***

Issuer

Profile
Novo Nordisk is a Denmark-based company. It is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company reports two business segments: Diabetes and Biopharmaceuticals. Diabetes division offers a range of diabetes products, ...
Novo Nordisk is a Denmark-based company. It is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company reports two business segments: Diabetes and Biopharmaceuticals. Diabetes division offers a range of diabetes products, including modern insulins, Biopharmaceuticals division provides treatments for people with haemophilia, growth hormone deficiency and for women experiencing symptoms of menopause / 08.12
Show more Hide
  • Issuer
  • Full borrower / issuer name
    Novo Nordisk A/S
  • Industry
    Pharmaceutical Preparation and Biotechnology

IFRS/US GAAP reports

2025
I q eng
II q eng
III q eng
IV q eng
2024
I q eng
II q eng
III q eng
IV q eng
2023
I q eng
II q eng
III q eng
IV q eng
2022
I q eng
II q eng
III q eng
IV q eng
2021
I q eng
II q eng
III q eng
IV q eng
2020
I q eng
II q eng
III q eng
IV q eng
2019
I q eng
II q eng
III q eng
IV q eng
2018
I q eng
II q eng
III q eng
IV q eng
Show all Hide

Indicators

News

07/06/2026 80% of Wegovy Pill Users Never Took a Weight Loss Drug Before. Does This Number Change the Entire Novo Nordisk Bear Case?
06/06/2026 Novo's Wegovy Pill Isn't Just Beating Expectations -- It's Obliterating Them. Is the Beaten-Down Stock a Buy Now?
06/06/2026 New issues: Novo Nordisk issued international bonds (CH1572819972, CH1572819964) in the amount of CHF 335, CHF 400 mln maturing in 2036, 2032 respectively.
03/06/2026 Here's What I Think Is Really Going on With Novo Nordisk Stock
03/06/2026 Bull vs. Bear: The Quick Take on Viking Therapeutics Stock
All organization news

Other stocks and deposit receipts

Domestic and international bonds of the issuer

Show all

Holders

Industry Leaders

Registration is required to get access.